Severe Refractory Immune Effector Cell-Associated Enterocolitis After Ciltacabtagene Autoleucel With Clonal Persistence of CAR-T Construct-Positive T Cells in the Gastrointestinal Tract: A Case Report
Case Reports in Oncology · 06.10.2026 · 19 (1) · 1887-1897
DOI: 10.1159/cro/abzag071 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 29.09.2026. Verfasst von Hira Cheema und 7 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Immune effector cell-associated enterocolitis is an emerging delayed toxicity after BCMA-directed CAR-T therapy for multiple myeloma. Severe cases may be refractory to corticosteroids and complicated by bowel injury, malnutrition, and prolonged need for parenteral nutrition. Case Presentation We report a 69-year-old man with kappa-free light chain multiple myeloma and AL amyloidosis who developed severe watery diarrhea, abdominal cramping, anorexia, weight loss, and debility several weeks after ciltacabtagene autoleucel. Initial infectious evaluation was negative. Endoscopic and histopathologic findings supported immune effector cell-associated enterocolitis, with epithelial apoptosis, crypt injury, and active inflammation. Gastrointestinal biopsies demonstrated a prominent atypical CD3-positive, CD4-positive T-cell infiltrate with relative CD7 loss and absence of CD8 expression in the atypical population. Molecular testing detected CAR-T construct transcripts and T-cell clonality, supporting clonal persistence or expansion of CAR-T construct-positive T cells in the gut without definitive evidence of overt CAR-T-cell lymphoma. His course was complicated by steroid-refractory enterocolitis, pneumatosis intestinalis, pneumoperitoneum, malnutrition, and the need for exploratory laparotomy without gross necrosis or frank perforation. He required bowel rest, total parenteral nutrition, intravenous immunoglobulin, and multimodal immunosuppression, including infliximab, vedolizumab, ruxolitinib, tacrolimus, budesonide, systemic corticosteroids, and cyclophosphamide.
Conclusion
This case highlights severe refractory immune effector cell-associated enterocolitis after ciltacabtagene autoleucel with biopsy-proven clonal persistence of CAR-T construct-positive T cells in gastrointestinal tissue. Tissue-based CAR-T construct testing and T-cell clonality assessment should be considered in severe or refractory post-CAR-T enterocolitis, particularly when biopsies show atypical T-cell infiltrates.
Zitieren
APA
Cheema, H., Naqvi, S., Moustafa, K. A. H. M., Zangari, M., Schinke, C., Thanendrarajan, S., Alapat, D., & Rhee, F. V. (2026). Severe Refractory Immune Effector Cell-Associated Enterocolitis After Ciltacabtagene Autoleucel With Clonal Persistence of CAR-T Construct-Positive T Cells in the Gastrointestinal Tract: A Case Report. Case Reports in Oncology, 19(1), 1887-1897. https://doi.org/10.1159/cro/abzag071
Vancouver
Cheema H, Naqvi S, Moustafa KAHM, Zangari M, Schinke C, Thanendrarajan S, et al. Severe Refractory Immune Effector Cell-Associated Enterocolitis After Ciltacabtagene Autoleucel With Clonal Persistence of CAR-T Construct-Positive T Cells in the Gastrointestinal Tract: A Case Report. Case Reports in Oncology. 2026;19(1):1887-1897. doi:10.1159/cro/abzag071
BibTeX
@article{Cheema2026,
author = {Cheema, Hira and Naqvi, Syed and Moustafa, Khadijah Adel Hassan Mahmoud and Zangari, Maurizio and Schinke, Carolina and Thanendrarajan, Sharmilan and Alapat, Daisy and Rhee, Frits Van},
title = {Severe Refractory Immune Effector Cell-Associated Enterocolitis After Ciltacabtagene Autoleucel With Clonal Persistence of CAR-T Construct-Positive T Cells in the Gastrointestinal Tract: A Case Report},
journal = {Case Reports in Oncology},
year = {2026},
volume = {19},
number = {1},
pages = {1887--1897},
doi = {10.1159/cro/abzag071}
}
EUVIMED